Prevention of fatal equine herpesvirus type 1 encephalitis in mice by immunization with a limited-replication cycle virus.

The research focuses on creating a potential vaccine for the prevention of Equine herpesvirus type 1 (EHV-1), a deadly pathogen in horses, causing lethal encephalitis in non-natural hosts, using a mutated version of the virus with limited replication.

Introduction

• The research paper focuses on EHV-1, a severe pathogen affecting horses and causing fatal encephalitis in non-natural hosts.
• The investigators previously demonstrated that the acylation of a tegument protein named UL11 is necessary for viral replication.

UL11 Modification and the 2/7/9 Mutant

• The researchers altered the normal structure of UL11 by replacing its glycyl and cysteinyl residues at positions 2, 7, and 9 that are generally acylated with alanyl residues. This alteration resulted in the creation of a mutant virus named the 2/7/9 mutant.
• The mutation also leads to the virus having a limited-replication cycle (LRC), meaning the virus replication stops after a few cycles.
• This mutated virus (2/7/9 mutant) showed potential as a candidate vaccine against fatal EHV-1 encephalitis.

Virulence Test and Vaccine Experiment

• A virulence test conducted on mice showed this mutated virus to be non-pathogenic while triggering an antibody response, demonstrating its safety and immune activity.
• The 2/7/9 mutant was further used to immunize mice against a zebra-borne EHV-1 variant, 94-137, in two separate trials.
• Each trial consisted of five immunized, five non-immunized, and five control mice.

Immune Response and Results

• The immunized mice displayed significantly fewer symptoms and lower mortality rates than their non-immunized counterparts, indicating the effectiveness of the 2/7/9 mutant-based vaccine.
• Interestingly, none of the mice in either trial developed neutralizing antibodies, indicating that the immunity provided was not due to neutralizing activity. The nature of this protective immunity is not described and could form the basis for further inquiries.
• Based on the lower clinical signs, fatalities, and no neutralizing activity, this study concludes that the 2/7/9 LRC mutant has promise as a potential vaccine against EHV-1 infections in non-natural hosts (like mice).